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Non-Small Cell Cancer (NSCLC) are frequently diagnosed at a later stage [1]. Treatment involves
chemotherapy and radiation, either sequentially or concurrently [2]. Concurrent therapy is more efﬁ-
cacious but also associated with more complications [4e6]. We present a rare care of trachea-pulmonary
ﬁstula formation after concurrent chemo and radiation in a patient with Squamous Cell Cancer (SCC).
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Case presentation
A 57-year-old man current everyday smoker, presented with
productive cough, hemoptysis, fever, chills and generalized weak-
ness. He had previously been diagnosed with poorly differentiated
SCC and was already on concurrent chemo-radiation. Initial chest
tomography (CT) of chest revealed a hilar mass measuring
3.2  3.3 cmwith some endo-bronchial component, narrowing the
right main bronchus (Fig. 1A). Patient completed concurrent chemo
radiation treatment with Cisplatin- Etoposide. A follow up chest CT
prior to the current presentation revealed signiﬁcant improvement.
On physical examination, patient was febrile and had cavernous
breath sounds in the right upper zone. CT chest with contrast
(Fig. 1B) revealed the development of thick walled cavity in the
right upper lobe (RUL) entered into the trachea just above the right
upper lobe bronchus, in the largest dimension the was 7.5  4.5 cm
in size. Sputum culture grew methicillin resistant Staphylococcus
Aureus (MRSA). Patient was treated with intravenous antibiotics.
However, due to continued fevers a bronchoscopy was done, this
revealed the large cavity, The bronchus intermedius that was
almost completely walled off and a stent to open up the lower lobe
was not placed due to the high risk of converting the cavity into aneet, Slot #555, Little Rock,
Ltd. This is an open access article uabscess (Fig. 1C). After discussion with the patient and his family
the goals of care were changed to comfort based therapies.
2. Discussion
NSCLC can present in stage III 25% of the time [1]. The standard
therapy for stage III NSCLC in patients with good performance and
minimal cancer related weight loss is concurrent chemo radiation
with curative intent [2]. Concurrent chemo-radiation (CCRT) can
improve the ﬁve year survival from 5% for radiotherapy alone and
15% with sequential chemo-radiotherapy to 25% [1]. This survival
beneﬁt is likely due to better loco-regional control of the disease
with concurrent treatment instead of sequential treatment or
radiotherapy alone [3].
CCRT is commonly associated with increased toxicity including
acute esophagitis and neutropenia [4]. In addition, CCRT can cause
local pulmonary toxicities, such as bronchial stenosis and fatal
pulmonary hemoptysis [5]. Tumor cavitation has been reported as
well. In one study, two out of 71 patients with stage III NSCLC un-
dergoing CCRT developed de-novo cavitation [6]. There are
increasing reports of NSCLC ﬁstulization following CCRT, especially
when using anti-angiogenic targeted therapy like Bevacizumab
[7e10]. Mortality rates are high with acquired bronchial tree
ﬁstulae especially if blood vessels were involved in the tract leading
to fatal hemorrhage [9]. In our patient, the cavity was surprisingly
large when taken in context of the absence of a parenchymal mass.
Tumor cavitation and subsequent ﬁstula formation may actuallynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Computed tomography scan of the chest showing a 3.2  3.3 cm hilar mass with endo-bronchial extension, narrowing the right main bronchus (A). Computed tomography
scan of the chest showing a thick walled cavity in the right upper lobe with tracheo-parenchymal ﬁstula just above the right upper lobe bronchus (B). Bronchoscopy revealed a
tracheoparenchymal ﬁstula connecting the right main bronchus to a large cavity in the right upper lobe, destroying majority of the right main bronchus and causing signiﬁcant
attenuation of the bronchus intermedius (C).
B. Alzghoul, N. Meena / Respiratory Medicine Case Reports 18 (2016) 22e23 23represent the true invasion by the tumor and response to CCRT. The
staphylococcus infection may also have played signiﬁcant role in
the cavity and ﬁstula formation.
Risk factors associated with bronchial tree ﬁstulization include,
a) high dose radiotherapy, b) tumor type, particularly squamous
cell cancer, c) superimposed infection, d) use of anti-angiogenic
factors like Bevacizumab [6e8]. Our patient had three of these
high risk factors.
The size of the ﬁstula and the dimensions of the cavity highlight
the importance of recognition and understanding of this process by
trainees.
3. Conclusion
Clinicians should be aware about the risk of tumor cavitation
and ﬁstulization associated with CCRT when used for NSCLC, even
in the absence of Bevacizumab. Tumor cavitation usually represents
treatment response, however a ﬁstula formation into blood vessels
or superimposed infections may have ominous some times fatal
connotation for the patient.
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